Physician profile
Alphonza Vester
NPI 1447311295
$1,748.08
in general payments reported to CMS, 2019-2025
12 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $147 · 2021: $278 · 2022: $537 · 2023: $156 · 2024: $86.40 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $450.19 | 2021-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $311.95 | 2019-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $267.47 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $220.56 | 2019-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $156.03 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Allergan, INC. | $140.78 | 2019-2020 | |
| Abbvie INC. | $91.88 | 2021-2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $48.94 | 2021-2022 | |
| Exact Sciences Corporation | $16.39 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $15.27 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.03 | 2022 | |
| Indivior INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alphonza Vester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.